Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cyclophosphamide + Motolimod + Pegfilgrastim |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Motolimod | VTX-2337|VTX-378 | TLR8 Agonist 9 | Motolimod (VTX-2337) binds to and activates Toll-like receptor 8 (TLR8), resulting in enhanced antibody-dependent cell-mediated cytotoxicity (PMID: 22128302, PMID: 28453702, PMID: 29931076). | |
Pegfilgrastim | Neulasta | GCSF-SD01 | Neulasta (Pegfilgrastim) is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |